Clinical Trials on Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Total 1058 results

Istituto Scientifico Romagnolo per lo Studio e...
Agenzia Italiana del Farmaco

Unknown

CDK4/6-inhibitor or Chemotherapy, in Combination With ENDOcrine Therapy, for Advanced Breast Cancer / KENDO (KENDO)

Metastatic Breast Cancer | Hormone Receptor Positive Breast Cancer | Hormone Receptor Negative Breast Cancer

Italy
Royal Marsden NHS Foundation Trust
Pfizer; Breast Cancer Now

Recruiting

PAveMenT: Palbociclib and Avelumab in Metastatic AR+ Triple Negative Breast Cancer (PAveMenT)

Metastatic Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Locally Advanced Breast Cancer | Recurrent Breast Cancer | ER+ Breast Cancer

United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Mirvetuximab Soravtansine as First Line in Treating Patients With Triple Negative Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditions

United States
Yale University

Completed

Assessment of the Decision-making Impact of the Breast Cancer Index in Recommending Extended Adjuvant Endocrine Therapy for Patients With Early Stage ER-positive Breast Cancer

Breast Cancer | Early Stage Estrogen Receptor (ER) Positive Breast Cancer

United States
Dana-Farber Cancer Institute
Genentech, Inc.

Recruiting

A Single Arm Phase II Study of ADjuvant Endocrine Therapy, Pertuzumab, and Trastuzumab for Patients With Anatomic Stage I Hormone Receptor-positive, HER2-positive Breast Cancer (ADEPT)

Breast Cancer | HER2-positive Breast Cancer | Hormone Receptor Positive Breast Cancer | Invasive Carcinoma of the Breast | Node Negative Breast Cancer | Micrometastasis Breast Cancer

United States
iOMEDICO AG
Novartis Pharmaceuticals

Completed

Ribociclib and Endocrine Therapy or Chemotherapy With or Without Bevacizumab for Metastatic Breast Cancer in First Line (RIBBIT)

Breast Cancer | Hormone Receptor Positive Tumor | HER 2 Negative Breast Cancer

Germany
Fudan University

Not yet recruiting

Study of SHR-A1921 Combined Adebrelimab in HR-positive, HER2-negative Advanced Breast Cancer

Advanced Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Hormone-receptor-positive Breast Cancer

China
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Recruiting

Stand up to Cancer: MAGENTA (Making Genetic Testing Accessible)

BRCA1 Gene Mutation | BRCA2 Gene Mutation | Estrogen Receptor Negative | HER2/Neu Negative | Progesterone Receptor Negative | Triple-Negative Breast Carcinoma | MLH1 Gene Mutation | RAD51C Gene Mutation | RAD51D Gene Mutation | BRIP1 Gene Mutation | PALB2 Gene Mutation | BARD1 Gene Mutation | MSH2 Gene Mutation | MSH6... and other conditions

United States
MedSIR
Pfizer

Completed

PALbociclib Rechallenge in horMone Receptor-posItive/HER2- Negative Advanced Breast Cancer (PALMIRA) (PALMIRA)

Breast Cancer | Advanced Breast Cancer | Hormone Receptor Positive Tumor | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

Spain, Germany, France, United Kingdom, Italy, Slovenia
Syndax Pharmaceuticals

Completed

Drug-Drug Interaction Study of Entinostat and Exemestane in Postmenopausal Women With ER+ Breast Cancer

Breast Cancer | Estrogen Receptor Positive Breast Cancer

United States
Spanish Breast Cancer Research Group
Seagen Inc.

Recruiting

Efficacy and Safety of the Combination of Trastuzumab Plus TUCAtinib Plus viNorelbine in Patients With HER2-positive Non-resectable Locally Advanced or Metastatic Breast Cancer (TrasTUCAN)

HER2-positive Metastatic Breast Cancer | Locally Advanced HER2 Positive Breast Carcinoma

Spain
Zhejiang Cancer Hospital

Recruiting

Dalpiciclib Combination With Fulvestrant and Compound Gossyfol Acetate Tablets in Women With CDK4/6 Inhibitor-refractory HR-positive HER-2 Negtive Metastatic Breast Cancer: a Phase 2 Clinical Trial.

Advanced HR-positive and HER2-negative Breast Cancer; CDK4/6 Inhibitor Treatment Failed

China
Samsung Medical Center
Asan Medical Center; Seoul National University Hospital; Ulsan University Hospital and other collaborators

Unknown

Fulvestrant (F)/Goserelin (G) vs Anastrozole (A)/G vs G for Premenopausal Women (FLAG)

Metastatic Breast Cancer | Estrogen Receptor Positive Tumor | Breast Cancer Nos Premenopausal

Korea, Republic of
Eastern Cooperative Oncology Group
National Cancer Institute (NCI)

Active, not recruiting

A Study to Evaluate Genetic Predictors of Aromatase Inhibitor Musculoskeletal Symptoms (AIMSS)

Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Stage IA Breast Cancer | Stage IB Breast Cancer | Stage IIIC Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Progesterone Receptor-positive Breast Cancer | Musculoskeletal Complications

United States
Jules Bordet Institute
Hoffmann-La Roche; Breast International Group; Institut Curie; International Drug...

Suspended

De-escalation Adjuvant Chemo in HER2+/ER-/Node-neg Early BC Patients Who Achieved pCR After Neoadjuvant Chemo & Dual HER2 Blockade (Decrescendo)

HER2-positive Breast Cancer | ER-Negative Breast Cancer | PR-Negative Breast Cancer | Node-negative Breast Cancer

Korea, Republic of, France, Israel, Belgium, Switzerland, Australia
University Hospital, Akershus
Vestre Viken Hospital Trust; Novartis

Recruiting

Neoadjuvant Treatment of Locally-advanced Breast Cancer Patients With Ribociclib and Letrozole (NEOLETRIB)

Breast Cancer | Locally Advanced Breast Cancer | ER-positive Breast Cancer | HER2-negative Breast Cancer | Luminal A Breast Cancer | Luminal B Breast Cancer

Norway
The Christie NHS Foundation Trust
Sahlgrenska University Hospital, Sweden

Active, not recruiting

Personalised Disease Monitoring in Metastatic Breast Cancer (PDM-MBC)

Breast Cancer Metastatic | Estrogen Receptor-positive Breast Cancer

United Kingdom, Sweden
Peking University

Recruiting

CT-based Radiomics of ALN pCR (ypN0) in Breast Cancer Undergoing NAC

HER2-positive Breast Cancer | Triple-negative Breast Cancer

China
Daiichi Sankyo

Recruiting

A Study to Assess the Effectiveness of Trastuzumab Deruxtecan in Chinese Breast Cancer Patients (REFRESH)

Breast Cancer | Advanced Cancer | HER2-positive Breast Cancer | HER2-low Breast Cancer

China
Spanish Breast Cancer Research Group
Pierre Fabre Laboratories; Puma Biotechnology, Inc.

Recruiting

Three Antidiarrheal Strategies in HER2+/HR+ Early Breast Cancer Patients Treated With Extended Adjuvant Neratinib (DIANER)

HER2 Positive Breast Cancer | Hormone Receptor Positive | Early-stage Breast Cancer

Spain
Fengxi Su

Unknown

Efficacy and Tolerability of Toremifene or Tamoxifen Therapy in Premenopausal Estrogen and Progesterone Receptor Positive Breast Cancer Patients

Breast Cancer Patients in Premenopausal | Estrogen and/or Progesterone Receptor Positive

China
UNICANCER
Breast International Group

Completed

Durvalumab and Endocrine Therapy in ER+/Her2- Breast Cancer After CD8+ Infiltration Effective Immune-Attractant Exposure (ULTIMATE)

Breast Cancer | Menopause | Estrogen Receptor Positive Tumor | Hormone Antagonist

France, Sweden, Spain
Novartis Pharmaceuticals

Recruiting

A NIS of Alpelisib in Combination With Fulvestrant in Postmenopausal Women, and Men, With HR+,HER2- , Locally Advanced or Metastatic Breast Cancer With a PIK3CA Mutation, After Disease Progression Following Endocrine Therapy as Monotherapy, in the Real-world Setting

Hormone Receptor Positive HER2 Negative Breast Cancer With a PIK3CA Mutation

Spain, Italy, Austria
University of Washington
National Cancer Institute (NCI)

Completed

Veliparib, Cisplatin, and Vinorelbine Ditartrate in Treating Patients With Recurrent and/or Metastatic Breast Cancer

Male Breast Cancer | Stage IV Breast Cancer | Triple-negative Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-negative Breast Cancer | Progesterone Receptor-negative Breast Cancer | HER2-negative Breast Cancer | Hereditary Breast/Ovarian Cancer - BRCA1 | Hereditary Breast/Ovarian Cancer...

United States
University of Pennsylvania

Active, not recruiting

FDG PET/CT in Breast Cancer Bone Mets

Bone Metastases | Estrogen Receptor Positive Breast Cancer

United States
Melinda Telli
Pfizer; BioMarin Pharmaceutical

Completed

Phase II Trial of Talazoparib in BRCA1/2 Wild-type HER2-negative Breast Cancer and Other Solid Tumors

Advanced Breast Cancer | HER2/Neu Negative | Triple-Negative Breast Cancer

United States
iOMEDICO AG
Novartis Pharmaceuticals; Arbeitsgemeinschaft fur Internistische Onkologie

Completed

Patient Preference for Everolimus in Combination With Exemestane or Capecitabine in Combination With Bevacizumab (IMPROVE)

Breast Cancer Recurrent | HER2/Neu-negative Carcinoma of Breast | Hormone Receptor Positive Malignant Neoplasm of Breast

Germany
Merrimack Pharmaceuticals
Sanofi

Completed

A Trial of Preoperative MM-121 With Paclitaxel in HER2-negative Breast Cancer

ER Positive, Her2 Negative Breast Cancer Patients | Triple Negative Breast Cancer Patients

United States
Abramson Cancer Center at Penn Medicine

Recruiting

Role of the Immune Environment in Response to Therapy in Breast Cancer

Breast Cancer | HER2-negative Breast Cancer | TNBC - Triple-Negative Breast Cancer | ER Positive Breast Cancer

United States
National Cancer Institute (NCI)

Completed

ONC201 in Recurrent/Refractory Metastatic Breast Cancer and Advanced Endometrial Carcinoma

Triple Negative Breast Cancer | Endometrial Cancer | Hormone Receptor Positive, HER2 Negative Breast Cancer

United States
Shanghai Proton and Heavy Ion Center

Recruiting

A Dose Escalation Study of Proton and Carbon Ion Irradiation for HER2 Positive and Triple Negative Breast Cancer

Triple Negative Breast Cancer | HER2-positive Breast Cancer

China
Samsung Medical Center

Active, not recruiting

Exosome as the Prognostic and Predictive Biomarker in EBC Patients

Triple Negative Breast Cancer | HER2-positive Breast Cancer

Korea, Republic of
H. Lee Moffitt Cancer Center and Research Institute

Terminated

Immune Response and Potential Booster for Patients Who Have Received HER2-pulsed DC1

Breast Cancer | Breast Cancer, Male | HER2-positive Breast Cancer | HER-2 Gene Amplification | Breast Cancer Female | HER2 Positive Breast Carcinoma | HER-2 Protein Overexpression

United States
Astellas Pharma Global Development, Inc.
Medivation LLC, a wholly owned subsidiary of Pfizer Inc.

Completed

A Study to Assess the Efficacy and Safety of Enzalutamide With Trastuzumab in Patients With Human Epidermal Growth Factor Receptor 2 Positive (HER2+), Androgen Receptor Positive (AR+) Metastatic or Locally Advanced Breast Cancer

Advanced Breast Cancer | HER2 Amplified | Human Epidermal Growth Factor Receptor 2 (HER2)

United States, Belgium, Canada, Italy, Spain, United Kingdom
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Active, not recruiting

ALRN-6924 and Paclitaxel in Treating Patients With Advanced, Metastatic, or Unresectable Solid Tumors

Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC v8 | Prognostic Stage III Breast Cancer AJCC v8 | Prognostic Stage IIIA Breast Cancer AJCC v8 | Prognostic Stage IIIB Breast... and other conditions

United States
Washington University School of Medicine
National Cancer Institute (NCI)

Completed

BKM120 and Fulvestrant for Treating Postmenopausal Patients With Estrogen Receptor-Positive Stage IV Breast Cancer

Stage IV Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer

United States
Peking University First Hospital

Completed

Validation of the CPS+EG, Neo-Bioscore and Modified Neo-Bioscore Staging Systems After PST of BC in China

Breast Cancer | Predictive Value of Tests | Neoadjuvant Therapy | Prognosis | HER2 | Neoplasm Staging | Estrogen Receptor | Histological Grade

China
Jennifer Lee Caswell-Jin
National Cancer Institute (NCI); QED Therapeutics, Inc.

Terminated

Study of Infigratinib in Combination With Tamoxifen in Hormone Receptor Positive, HER2 Negative, FGFR Altered Advanced Breast Cancer

Breast Cancer | HER2-negative Breast Cancer | ER Positive Breast Cancer | PR-Positive Breast Cancer

United States
Ruijin Hospital

Recruiting

Neoadjuvant Nab-paclitaxel in Triple-negative or HER2-positive Breast Cancer (NeoPATH)

Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer

China
UNC Lineberger Comprehensive Cancer Center
Incyte Corporation

Withdrawn

Parsaclisib in Newly Diagnosed Stage I-IIIC Triple Negative or HER2+ Breast Cancer (LCCC1820)

Breast Cancer | Breast Neoplasms | Triple Negative Breast Cancer | HER2-positive Breast Cancer
Sun Yat-Sen Memorial Hospital of Sun Yat-Sen University
Jiangsu HengRui Medicine Co., Ltd.

Active, not recruiting

Phase II Neoadjuvant Pyrotinib Combined With Neoadjuvant Chemotherapy in HER2-low-expressing and HR Positive Early or Locally Advanced Breast Cancer: a Single-arm, Non-randomized, Single-center, Open Label Trial

Breast Cancer | Neoadjuvant Therapy | Hormone Receptor-positive Breast Cancer | HER2-low-expressing Breast Cancer

China
University of Arizona
National Cancer Institute (NCI); GlaxoSmithKline

Terminated

Neo-adjuvant Therapy With Anastrozole Plus Pazopanib in Stage II and III ER+ Breast Cancer

Male Breast Cancer | Stage II Breast Cancer | Stage IIIA Breast Cancer | Stage IIIB Breast Cancer | Recurrent Breast Cancer | Estrogen Receptor-positive Breast Cancer | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast

United States
Puma Biotechnology, Inc.

Not yet recruiting

A Study of Alisertib in Combination With Endocrine Therapy in Patients With HR-positive, HER2-negative Recurrent or Metastatic Breast Cancer (ALISCA-Breast1)

Metastatic Breast Cancer | Recurrent Breast Cancer | Hormone Receptor Positive HER-2 Negative Breast Cancer

United States
Jules Bordet Institute
KU Leuven; University of Milan

Not yet recruiting

Ketorolac and Pregabalin Effects on breaSt Cancer (KePreSt) (KePreSt)

Early-stage Breast Cancer | Estrogen-receptor-positive Breast Cancer

Belgium
Andrei Iagaru
General Electric

Completed

68-Ga-RM2 PET/MRI in Imaging Patients With Estrogen Receptor-Positive Breast Cancer

Breast Carcinoma | Estrogen Receptor Positive

United States
Eli Lilly and Company

Completed

A Study of Abemaciclib (LY2835219) in Women With HR+, HER2+ Locally Advanced or Metastatic Breast Cancer (monarcHER)

HER-2 Positive Breast Cancer | Hormone Receptor Positive Breast Cancer

Spain, United States, Korea, Republic of, Belgium, France, Germany, Italy, Australia, Argentina, Canada, United Kingdom, Mexico, Brazil, Greece
Consorzio Oncotech
Clinical Research Technology S.r.l.

Unknown

Fulvestrant and EVerolimus Plus EXemestane in Metastatic Breast Cancer (FEVEX)

Breast Cancer | Metastatic Breast Cancer | Hormone Receptor Positive Tumor | Human Epidermal Growth Factor 2 Negative Carcinoma of Breast | Locally Advanced Malignant Neoplasm

Italy
Kathy Miller
Pfizer; Astex Pharmaceuticals, Inc.; Van Andel Institute Stand Up to Cancer Team

Completed

Study of ASTX727 Plus Talazoparib in Patients With Triple Negative or Hormone Resistant/HER2-negative Metastatic Breast Cancer

Metastatic Breast Cancer | Triple Negative Breast Cancer | Hormone Receptor Positive Tumor

United States
European Institute of Oncology

Recruiting

Vabb After Neoadjuvant Therapy to Avoid Surgery-pCR to Avoid Breast Surgery (BETTY-CRASY)

Breast Cancer | Triple Negative Breast Cancer | HER2-positive Breast Cancer | Neoadjuvant Chemotherapy

Italy
M.D. Anderson Cancer Center
National Cancer Institute (NCI)

Completed

Durvalumab and Tremelimumab Before Surgery in Treating Patients With Hormone Receptor Positive, HER2 Negative Stage II-III Breast Cancer

Anatomic Stage II Breast Cancer AJCC v8 | Anatomic Stage IIA Breast Cancer AJCC v8 | Anatomic Stage IIB Breast Cancer AJCC v8 | Anatomic Stage III Breast Cancer AJCC v8 | Anatomic Stage IIIA Breast Cancer AJCC v8 | Anatomic Stage IIIB Breast Cancer AJCC v8 | Anatomic Stage IIIC Breast Cancer AJCC... and other conditions

United States

Clinical Trials on Estrogen Receptor-Positive, HER2-Negative Advanced Breast Cancer

Sponsors and Collaborators

Medical Conditions

Drug Interventions

CROs by country

CROs in Myanmar

Conditions

Rare Diseases

Drug Interventions

Dietary Supplements

Sponsor/Collaborators

Locations